-
Medical Information Documents
-
Data in Virologically Suppressed Patients
-
Treatment-Emergent Resistance Data
-
Data in Viremic Patients
-
Dosage, Administration, and Delivery
-
Implementation into Clinical Practice
-
Status in DHHS and IAS Guidelines
-
Safety Data
-
Drug Interactions
-
Data in Pediatrics
-
Special Populations
-
Patient Reported Outcomes
-
Storage and Stability
-
-
On Demand Medical Videos
-
Congress Data
Discussing CABENUVA Data at AIDS 2022
Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care CentersDiscussing CABENUVA Data at AIDS 2022
Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care CentersCabenuva Post CROI 2022 Discussion
Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
Mark Lewandowski, PharmD —Medical Director, ViiV HealthcareCabenuva Post CROI 2022 Discussion
Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
Mark Lewandowski, PharmD —Medical Director, ViiV HealthcareATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, CabotegravirATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, CabotegravirPost-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs -
Clinical Trials Data
Cabenuva Post CROI 2022 Discussion
Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
Mark Lewandowski, PharmD —Medical Director, ViiV HealthcareCabenuva Post CROI 2022 Discussion
Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
Mark Lewandowski, PharmD —Medical Director, ViiV HealthcareATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, CabotegravirATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, CabotegravirThe ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice
Paula Teichner, PharmD, AAHIVP, Regional Medical Lead
The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice
Paula Teichner, PharmD, AAHIVP, Regional Medical LeadPost-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs -
Data in Virologically Suppressed Patients
-
Safety Data
-
-
Implementation Resources
Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Find My ViiV MSL
Easily find the ViiV Medical Science Liaison (MSL) in your area.
Talk to a Medical Expert
Connect now with a live ViiV Medical Expert.
Request a Scientific Discussion
Submit a request for additional information from a ViiV Medical Expert.
Chat Live
Get immediate assistance from a ViiV Healthcare Professional.
Call 1‑888‑226‑8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch